Background Childhood CNS primitive neuro-ectodermal brain tumours (PNETs) are very aggressive brain tumours for which the molecular features and best treatment approaches are unknown. We assessed a large cohort of these rare tumours to identify molecular markers to enhance clinical management of this disease. Interpretation LIN28 and OLIG2 are promising diagnostic and prognostic molecular markers for CNS PNET that warrant further assessment in prospective clinical trials.
Introduction
Brain tumours are the most common paediatric solid neoplasms 1 and a leading cause of cancer-related morbidity and mortality in children. 2 Embryonal tumours are the largest group of malignant paediatric brain tumours and include medulloblastoma, atypical rhabdoid teratoid tumour, and CNS primitive neuro-ectodermal brain tumours (PNETs). Despite histological resemblance to medullo blastoma, patients with CNS PNETs fare poorly even with intensifi ed therapy designed for patients with metastatic medulloblastoma. 3, 4 By contrast with this disease, in which substantial progress has been made in molecular understanding 5, 6 and clinical outcomes, 7 the molecular and cellular make-up of CNS PNET is largely unknown 8 and tumour treatments are often ineff ective. To improve outcomes from CNS PNET, delineation of the cellular and molecular pathogenesis of CNS PNET will be important to inform diagnosis, prognosis, and design of tumour-specifi c treatments.
CNS PNETs are predominantly hemispheric tumours and make up about 3-5% of all paediatric brain tumours. Such cancers are histologically heterogeneous with variable neuronal, ependymal, or glial diff erentiation 9 and can be challenging to diagnose by routine histopath ology. 10 Although diagnostic techniques and molecular-based tumour classifi cations have improved for atypical rhabdoid teratoid tumours 11 and medulloblastoma, the working classifi cation for CNS PNET is not settled and thus therapeutic and molecular studies can be challenging. In recent studies, our research groups identifi ed a distinctly aggressive subgroup of CNS PNETs that showed fre quent amplifi cation of an oncogenic miRNA cluster (C19MC). 12, 13 However, the molecular composition of most CNS PNETs is unknown. Although genomic studies suggest sub stantial heterogeneity in DNA copy number profi les, 8, 12, 14 the signifi cance of these fi ndings in relation to clinical phenotypes is unclear. Similarly, geneexpression studies of small cohorts 12, 15 have yielded few insights into the clinical diversity of CNS PNETs. In this study, we undertook a multicentre, international collaboration with the aim of providing a concerted molecular analysis of a substantial number of primary CNS PNETs.
To assess clinical signifi cance of potential CNS PNET molecular subgroups, we examined whether subgroups diff ered in patient characteristics and outcome.
Methods

Participants and study design
We obtained 254 samples with an institutional diagnosis of CNS PNET from participating institutions including six registered Children's Cancer and Leukaemia Group centres in the UK and the Cooperative Human Tissue Network in Columbus, OH, USA (centres listed in the appendix). CNS PNET tissue microarrays used in this study were constructed at the Hospital for Sick Children (Toronto, ON, Canada), 12 University of Nottingham (Nottingham, UK), 14 and the Institute of Cancer Research (Sutton, UK). All collected samples were initially reviewed for age of patient, location, and primary tumour occurrence (fi gure 1) and then subject to histopathologic review by CEH, who was masked to fi ndings of previous assessments at the other centres. Samples were tested for loss of INI1 immunoreactivity or changes in INI1 by sequencing or multiplex ligation-dependent probe amplifi cation ana lyses to rule out misdiagnosed atypical rhabdoid teratoid tumours. We included only hemispheric tumours diag nosed as CNS PNET according to the 2007 WHO CNS tumour classifi cation criteria 9 without mutations in INI1. For correlative analyses with clinical characteristics, we included only tumours with complete clinical information (full details of the patients and tumour information is listed in the appendix). We obtained tumour samples and clinical information with consent as per protocols approved by the hospital research ethics boards at participating institutions.
Procedures
All tumour samples confi rmed to be CNS PNET and with snap frozen tumour material were processed for gene expression or DNA array analyses to initially establish tumour molecular subgroups. grouping for samples with only formalin-fi xed paraffi nembedded (FFPE) materials available were determined with immunohistochemical analyses. All tumour samples with established molecular grouping in formation and clinical data for patients' demographics, metastatic status, and survival were then examined to determine whether molecular subgroups correlated with specifi c CNS PNET phenotypes.
To assess gene expression and DNA copy number profi les, we extracted RNA from 51 primary CNS PNET samples and DNA from 77 samples with standard methods. We used Illumina Omni 2.5M single-nucleo tide polymorphism (SNP) for ultra-high resolution copy number analyses (interrogating 2·5 million SNPs) and Illumina HT-12.v4 gene-expression arrays (San Diego, CA, USA) to generate DNA copy number and gene expression profi les. We did DNA and RNA hybridisations at the Centre of Applied Genomics Facility at the Hospital for Sick Children, according to the manufacturer's protocol.
For the gene expression profi les, we did multiple unsupervised analyses to identify molecular subgroups of CNS PNETs. To defi ne genes or pathways that characterise each CNS PNET subgroup, we then did supervised analyses of each subgroup relative to the others, and examined the most highly diff erentially expressed gene sets between subgroups for gene and pathway enrichment. To assess the clinical signifi cance of identifi ed molecular subgroups, we sought markers of each subgroup that could be examined by immunohistochem istry on a larger cohort of clinically well characterised tumours. We did quantitative RT-PCR analyses to validate group-specifi c gene clusters identifi ed by supervised analyses and examined expression levels of individual genes across groups to identify the most robust, upregulated loci that can distinguish tumour subgroups.
To determine the relationship of copy number changes to molecular subgroups, we included 59 (77%) of 77 tumours with copy number profi les that had established molecular grouping.
The appendix shows details of molecular analyses done on individual tumour samples. All data are deposited in the Wellcome Trust, European Genome-Phenome Archive (accession number EGAS00000000116).
For gene-specifi c quantitative RT-PCR validation of array data, we amplifi ed 10 ng cDNA synthesised from 1 μg of RNA (TaqMan Reverse Transcription Kit, Applied Biosystems, Burlington, ON, Canada) by use of specifi c TaqMan probes-primer sets (see appendix) and determined mRNA expression levels relative to actin with the ΔC t method. We did all RT-PCR assays in triplicate. Immunohistochemical analyses of tumour tissue microarray or FFPE tumour slides were done by the Pathology Research Program laboratory at the University Health Network (Toronto, ON, Canada). We treated all tissue sections with heat-induced epitope retrieval and blocked for endogenous peroxidase and biotin. We assessed expression of markers for primitive neural, glial (nestin, glial fi brillary acidic protein [GFAP]) or neuronal (synaptophysin) diff erentiation-which are measurements conventionally used in histopathological diagnosis of CNS PNET-for all tumours. The anti bodies used in this study were anti-LIN28 (Cell Signalling Technology, Boston, MA, USA), OLIG2 (Immuno-Biological Laboratories, Minneapolis, MN, USA), GFAP (DAKO, Burlington, CA, USA), and synaptophysin (Millipore, MA, USA). Antibody reactions were visual ised with a Biogenix detection kit (BioGenex Laboratories, San Ramon, CA, USA). Immunoreactivity for LIN28, GFAP, and synaptophysin were scored manually on the basis of intensity (1 was low, 2 was moderate, and 3 was high) and distribution of stains (1 was ≤10%, 2 was 10-50%, and 3 was >50%). OLIG2 immunostains were quantifi ed with the Aperio Scanscope (Aperio, Vista, CA, USA) system and the ImageScope software nuclear immunohistochemistry Normal testicular tissue (human and mouse) was used as a positive control for LIN28 and oligodendroglioma tumour tissue was used as a positive control for OLIG2 immunostains; samples processed in parallel without primary antibodies were used as negative controls. DP and TC scored all immuno histochemistry stains while masked to cancer status, which were reviewed by AH and CEH. FISH was done on FFPE tissue microarrays or individual slides with established protocols. To confi rm robustness of LIN28 and OLIG2 immunohistochemistry for subgrouping, we tested an initial cohort of 22 samples with subgroups established by gene expression studies for LIN28 and OLIG2 expression by immunohistochemistry (appendix) We used MYCN (2p24) and p16 (9p21) specifi c PlatinumBright550 probe with corresponding LAF (2q11) and 9q21 PlatinumBright495 control probes (Kreatech, Stretton Scientifi c, Stretton, UK).
Statistical analysis
We classifi ed CNS PNETs into molecular subgroups by unsupervised hierarchical clustering, non-negative matrix factorisation, 16 and principal component analyses of genes with the highest coeffi cient of variation with the Partek Genomics Suite version 6.5 (Partek, St Louis, MO, USA). We assessed genes enriched within tumour sub groups with a supervised t test adjusted for multiple hypotheses testing with the false-discovery-rate method. Ingenuity pathway analyses were done on supervised gene sets to identify canonical signalling pathways in each tumour subgroup. To establish regions of copy number gains and losses, inferred copy number data were generated with the Illumina Genome studio software and were imported into Partek for copy number variation partitioning-segmentation analyses with a SNP window of 150. We then determined signifi cance of copy number alterations in tumour subgroups with Fisher's exact test. We used the log-rank analysis with the Kaplan-Meier method to compare survival times and χ² analyses to compare the proportion of survivors across tumour subgroups, whereas ANOVA was used to assess signifi cance of tumour subgroups in relation to age. To analyse the signifi cance of molecular subgroups in relation to sex and metastatic status at diagnosis, we compared features in an individual molecular subgroup to a pooled cohort of the other two molecular subgroups with Fisher's exact test. Adjustment for multiple testing was not done because patients with complete information available for every clinical parameter varied. A p value of less than 0·05 was regarded as signifi cant for all analyses. All statistical analyses were done with SPSS version 19·0.
Role of the funding source
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. DP, SM, RGG, and AH had access to the raw data. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit for publication.
Results
Unsupervised hierarchical and non-nega tive matrix factorisation clustering with 200-1000 genes consistently identifi ed three distinct molecular sub groups of CNS PNET, with non-negative matrix factorisation analyses suggesting a strongest cophenetic coeffi cient at k=3 (fi gure 2, appendix). Principle com ponent analyses suggested that group 1 tumours, which have frequent C19MC locus amplifi cation, segregated distinctly, whereas group 2 and 3 tumours showed greater proximity and some overlap (appendix).
Supervised analyses revealed that the three subgroups showed signifi cant diff erences in neural lineage and diff erentiation genes (fi gure 2). Expression profi les of group 1 were most signifi cantly enriched for genes 17 which are implicated in stem-cell pluripotency, were among the most overexpressed genes with nearly 20-30 fold greater expression in group 1 as compared with group 2 and group 3. In group 2 tumours, OLIG1/2, SOX8/10, and BCAN (which are markers of oligoneural diff erentiation 18 ) were the most upregulated genes, whereas group 3 tumours showed reduced ex pression of neural diff erentiation genes but upregulation of epithelial and mesenchymal diff erentiation genes including COL1A2, COL5A, FOXJ1, 19 and MSX1. 20 Pathway enrichment analyses also suggested significant diff erences in the signalling gene profi les of every tumour subgroup (fi gure 2). Consistent with diff erential enrichment of lineage related genes in tumour sub groups, we noted signifi cant diff erences in expression of axonal guidance genes among the CNS PNET subgroups. Genes involved in WNT signalling were upregulated in group 1 tumours and those involved in SHH signalling were downregulated in group 2 tumours, whereas TGF-β and PTEN signalling pathway genes were specifi cally upregulated in group 3 tumours.
Immunohistochemistry and quantitative RT-PCR analyses showed that LIN28, OLIG2, and IGF2 were highly diff erentially expressed in CNS PNET group 1, group 2, and group 3 tumours, respectively (fi gure 3, appendix). IGF2 protein expression could not be reliably scored on tumour samples (appendix); however, immunohistochemical analyses for LIN28 and OLIG2 were robust and correlated with gene-expression levels as established by arrays and quantitative RT-PCR analyses. Immunohistochemical analyses on a test cohort of 22 tumours indicated that extent of cytoplasmic LIN28 and nuclear OLIG2 immunostaining also correlated with tumour subgroup assignment based on gene-expression profi les (appendix). LIN28 was expressed at high levels and OLIG2 was expressed at low levels in group 1 tumours, whereas group 2 tumours had high OLIG2 and little LIN28 immunopositivity. LIN28 and OLIG2 protein expression was low or absent in group 3 tumours (fi gure 3).
In the LIN28 and OLIG2 immunohistochemical analyses of an additional 72 primary CNS PNETs with only FFPE samples available for analyses, 15 tumours had inconclusive immuno histochemical analyses (appendix). Overall, we were able to assign 108 of 142 primary CNS PNETs to molecular subgroups on the basis of gene expression or immunohistochemical analyses of LIN28 or OLIG2 protein expression (or both measures; tables 1, 2, appendix). We classifi ed 29 (27%) tumours as group 1, 36 (33%) as group 2, and 43 (40%) as group 3 (appendix). Group 1 tumours with high LIN28 expression generally also expressed high levels of nestin, but had little to no expression of GFAP. GFAP and synaptophysin expression varied substantially between each of the tumour groups and did not consistently correlate with LIN28 or OLIG2 expression. Notably, quantitative RT-PCR and expression analyses suggested that expression of other neuronal diff erentiation genes also do not diff er signifi cantly among the molecular subgroups of CNS PNETs (appendix). These fi ndings collectively suggest the limitations of conven tional markers to capture the molecular diversity of CNS PNETs.
CNS PNET subgroups have distinct DNA copy number patterns. Apart from the C19MC miRNA amplicon that we previously identifi ed, 12 we noted few other recurrent high level copy number gains or amplifi cation. Focal MYCN and CDK4 amplifi cation was detected in isolated tumours. Deletions centred on CDKN2A/2B were the most frequent copy number aberration noted (10 [12%] of 77 tumours; appendix). To establish whether there were characteristic copy number aberrations within the CNS PNET subgroups, we analysed the copy number patterns of a subset of 59 tumours that could be subgrouped on the basis of LIN28 and OLIG2 gene or protein expression (appendix). Copy number analyses showed that, in addition to chr19q13·41 amplifi cation and chromosome 2 gains, group 1 tumours had frequent gains of chromosome 3. Group 2 tumour copy number aberration profi les were characterised by more frequent gains of chromosome 8p (p=0·027), 13 (p=0·009), and 20 (p=0·039) compared with group 1 and 2 tumours. Notably, only group 2 and 3 tumours had frequent chromosome 9p loss centred on the CDKN2A/2B locus. Moreover, group 3 tumours showed frequent loss of chromosome 14 (p=0·009). Thus, CNS PNET subgroups correlate with distinct gene expression as well as genomic profi les.
To determine the clinical signifi cance of CNS PNET molecular subgroups, we examined whether subgroups diff ered in patient characteristics and outcome. Of 108 patients for which tumour subgrouping could be established, demographic data on sex, age, survival, and tumour stage were available for 107, 100, 58 and 66 cases, respectively (tables 1 and 2; appendix). Molecular subgroups were associated with distinct clinical phenotypes. Sex and age distribution diff ered between the three molecular CNS PNET subgroups. Group 1 tumours were more often noted in female patients than were group 2 and group 3 tumours (fi gure 4, table 1). Patients with group 1 and group 2 tumours had bimodal age distributions with peak incidence at opposite age spectra, whereas patients with group 3 tumours had a single peak between 4-8 years. Patients with group 1 tumours were younger than were those with group 2 or group 3 tumours (table 1) . 47 (47%) of 100 patients with data for age were 4 years old or younger; however young patients were signifi cantly over-represented in group 1 as compared with group 2 and group 3 (p=0·001; fi gure 4, table 1).
Molecular subgroups of CNS PNET also had signifi cant diff erences in incidence of tumour metastases. Patients with group 3 tumours had the highest incidence of disseminated disease at diagnosis (fi gure 4, table 1). Although metastatic disease is reportedly more frequently in younger children with embryonal brain tumours, analyses done with stratifi cation for age (≤4 years vs >4 years) showed the incidence of tumour metastases diff ered signifi cantly in CNS PNET subgroups diagnosed in older children (fi gure 4, table 2). More patients aged older than 4 years at diagnosis in group 3 presented with metastatic disease than did those in group 1 or group 2 (table 2). The proportion of non-metastatic to metastatic tumours in this age group diff ered signifi cantly in comparisons of group 3 to a combined cohort of group 1 and group 2 patients and to group 2 patients alone (fi gure 4, table 2). Log-rank analysis of all tumour age groups showed that overall survival for patients in group 1 was signifi cantly shorter than it was for patients in group 2 and group 3 (fi gure 5, table 1). With the exception of two longer term survivors, all patients in group 1 were deceased within 4·2 years of diagnosis. Because most group 1 tumours arise in younger children who are often treated heterogeneously with radiation-sparing thera peutic approaches due to worries of neurocognitive damage, 3, 21 we examined whether the poor prognostic association of LIN28 expression in group 1 tumours held true for older children who are conventionally prescribed intensifi ed treatment regimens with higher dose craniospinal irradiation. Moreover, because most infant brain tumour protocols enrol patients up to 3-4 years of age, 3,4,21 we stratifi ed patients by age at the cutoff of 4 years, to remove age and potential treatment biases on survival. Although overall survival for all young patients was similarly poor, children older than 4 years of age with LIN28 group 1 tumours fared signifi cantly worse (median survival of 0·5 years, 95% CI 0·0-1·0; p=0·004) than did patients older than 4 years of age in group 2 (1·8 years, 1·5-2·2) and group 3 (4·8 years, 1·6-8·0). These fi ndings suggest that immunopositivity for LIN28 identifi es a particularly high risk group of CNS PNET across ages.
Discussion
Advances in treatment for childhood CNS PNET have been diffi cult because of the low incidence of the disease, 9 incomplete understanding of the clinical and biological spectra of disease, and an absence of specifi c markers to aid histopathological diagnoses (panel). 8, 10 In this study, we aimed to integrate gene expression, copy number, and immuno histochemical analyses to characterise 142 primary hemispheric CNS PNETs. Diff erential expres sion of cell lineage markers, LIN28 and OLIG2, distinguishes three molecular subgroups of CNS PNET and identifi es CNS PNET subgroups at very high risk of metastases and treatment failures and distinct demographic features. Primitive neural group 1 tumours, with frequent C19MC amplifi cation and high LIN28 expression, are distinctly aggressive tumours arising in young children. Oligoneural group 2 tumours, which have high OLIG2 expression, arise in older children and are frequently localised. Mesenchymal group 3 tumours, which have low LIN28 and OLIG2 expression, are associated with a high incidence of metastases and occur at all ages. Group 1 tumours were more frequently in females, whereas group 2 and group 3 tumours arose more frequently in males. These markers are promising molecular identifi ers for childhood CNS PNET that could be applied to refi ne tumour diagnosis, classifi cation, and treatment risk stratifi cation. Comprehensive clinical and biological data for a large cohort of primary CNS PNETs are not available. Previous molecular studies have often included a spectrum of CNS PNETs including rare variants, tumours arising in diff erent anatomical locations such as pineoblastomas, and medulloblastoma. 8 Because the biological relation of CNS PNET arising in diff erent anatomical locations is unclear, we restricted our study to tumours arising in the cerebral hemispheres, making up most childhood CNS PNET.
Although CNS PNETs are generally regarded as mainly a disease of younger children, analysis of our data suggests that more than 50% of CNS PNETs arise in older children (>4 years) and that CNS PNETs have an age-dependent distribution of molecular subgroups. The strong association of lineage-specifi c gene-expression signatures and age with specifi c tumour subgroups suggests molecular subgroups of hemispheric CNS PNET might derive from diff erent precursor cell stages or type. Specifi cally, transcriptional signatures of group 1 tumours (enriched for CD133, CRABP1, LIN28, and ASCL1) and group 2 tumours (enriched for OLIG1/2) suggest that the former arose from early neural progenitors and the latter from oligoneural progenitors. The possible cellular origin of group 3 CNS PNETs, which are enriched for mesenchymal diff erentiation genes including ZIC2 22 and LHX2, 23 is less clear. Studies of human brain tumours and brain tumour models suggest that cell lineage-related gene-expression signatures often correlate with and underlie clinical and biological heterogeneity in a spectrum of CNS tumours including malignant gliomas, 24 ependymoma, 25 and medulloblastoma. 26 In addition to age and sex, we noted signifi cant diff erences in survival and metastatic tendency between the three CNS PNET subgroups. We noted poorest survival in the primitive neural group 1 tumours identifi ed on the basis of LIN28 expression, irrespective of age or metastatic status. Together with previous fi ndings that link C19MC amplifi cation with a distinctly aggressive CNS PNET phenotype, 12,13 our study further emphasises CNS PNET with C19MC amplifi cation and/or LIN28 expression as a unique clinicopathological entity and suggests LIN28 immunohistochemistry could be an important, new diagnostic tool for this distinct group of embryonal brain tumours.
Overall survival for group 2 and group 3 tumours, which more commonly presented in older children, did not diff er signifi cantly (p=0·087), but there was some suggestion that children older than 4 years with group 3 mesenchymal lineage tumours had better survival (11 [52%] of 21 children were alive at last assessment) than did those with group 2 tumours (fi ve [26%] of 19 were alive at last assessment; table 2). This fi nding is surprising, because group 3 tumours had the highest incidence of metastases at diagnosis, which is linked to poorer outcomes in medulloblastoma and other embryonal brain tumours. These observations suggest greater sensitivity of group 3 tumours to medulloblastomatype drugs, which are usually prescribed to older children with CNS PNET, and might suggest greater biological relatedness of group 3 CNS PNETs to medulloblastoma. However, treatment designed for high-risk medulloblastoma with higher-dose craniospinal irradiation, which is usually prescribed to older children with CNS PNET, might not off er additional therapeutic benefi t for most group 2 CNS PNETs. Our fi ndings underscore the clinical hetero geneity of CNS PNET arising in the cerebral hemisphere and suggest that group 2 and group 3 CNS PNET need diff erent therapeutic approaches tailored to their specifi c biology.
Our study confi rms the documented poor overall outcome of CNS PNETs across age groups and emphasises the need to seek new treatment strategies for this aggressive disease. Pathway enrichment analyses suggested that the non-canonical WNT pathway predominates in group 1 tumours and thus could be an attractive target for treatment. Group 1 tumours also
Panel: Research in context
Systematic review
We searched PubMed and Google Scholar for molecular studies of childhood CNS primitive neuro-ectodermal brain tumours (PNETs) published in English between Jan 1, 1985, and Dec 31, 2011, with the search terms "childhood PNET", "CNS-PNET", "supratentorial PNET", and "embryonal brain tumours" (because CNS PNETs were often included in molecular studies of medulloblastoma).
Interpretation
Present treatment strategies for CNS PNETs are largely designed based on the cancer's close histological similarities to medulloblastoma, although such therapy is not as effi cacious in CNS PNETs. A tailored treatment for CNS PNET is needed to exploit their distinct biology; however, molecular studies of CNS PNETs have been restricted by rare disease incidence and scarcity of robust diagnostic markers. Apart from two recent studies 12, 14 by our group and a previous review, 8 molecular studies of CNS PNETs have been restricted to small cohorts of CNS PNETs from various anatomical sites and diagnoses made on various histopathological criteria. Our integrated genomic analyses of primary CNS PNET tumour samples were restricted to the cerebral hemispheres and tumours that met the 2007 WHO CNS classifi cation criteria for CNS PNET and were confi rmed with genetic methods to be non-rhabdoid tumours. In keeping with previous clinical observations, we show that CNS PNET makes up a heterogeneous spectrum of tumours and defi nes three molecular subtypes of CNS PNETs with distinct survival and metastatic features. Our study provides the fi rst molecular prognostic markers for CNS PNET, and is a substantial advance towards biology-driven treatment strategies for this disease.
showed signifi cant upregulation of the SHH signalling pathway, suggesting that novel SHH pathway inhibitors in clinical trials 27 might be attractive new drugs for this subgroup. Of note, CRABP1, a retinoid-binding protein known to change retinoic metabolism and confer alltrans retinoic acid resistance, 28 is very highly expressed in the group 1 CNS PNET. Thus retinoic acid, which is being tested in high-risk medulloblastoma and CNS PNET cooperative group clinical trials for older children, might be of little therapeutic benefi t in group 1 CNS PNETs.
By contrast with group 3 tumours that showed upregulation of several canonical pathways, the oligoneural group 2 tumours showed downregulation of both SHH and WNT signalling pathways. Although we noted higher expression of PDGFRA and ERBB3 in this subgroup (appendix), pathway analyses did not show signifi cant global enrichment of receptor tyrosine sig nalling pathways. However, these potential therapeutic pathways might emerge with studies of larger cohorts, and further delineation of CNS PNET subgroups. Consistent with the higher incidence of metastases noted in group 3 tumours, we identifi ed substantial activation of semaphorin signalling genes in this tumour group. In addition to activated TGFβ signalling, group 3 tumours showed upregulation of PTEN signalling and IGF2 expression, thus making these pathways and genes attractive targets for potential subgroup specifi c therapies.
Our data show that hemispheric tumours diagnosed as CNS PNET in children can be diff erentiated into subgroups with distinct survival and metastatic characteristics on the basis of lineage markers, LIN28 and OLIG2. Because our study was restricted to hemispheric CNS PNETs, assessment of the signifi cance of these molecular groupings to non-hemispheric CNS PNETs, such as pineoblastoma, will be important. Our study was limited by sample size and the absence of an independent validation cohort due to the rare incidence of CNS PNET. Nonetheless, we anticipate that LIN28 and OLIG2, which are the fi rst molecular markers reported for CNS PNET to date, will help identify high-risk group 1 tumours for new therapies, allow tailoring of chemoradiotherapy for patients with group 2 and group 3 tumours (which diff er strikingly in metastatic potential), and will help establish a working classifi cation of CNS PNETs. Our report under scores the importance of concerted, collaborative eff orts to study large retrospective cohorts of tumours and patients to accelerate biological and ultimately therapeutic studies of rare tumours.
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